Cytocom (CBLI) Cash Flow Statement

Click line-items for a historical chart and %

CASH FLOWS FROM OPERATING ACTIVITIES
Net income/(Loss)	-1.42M
Adjustments to reconcile net income/(loss) to net cash used in operating activities:
Depreciation
Amortization
Noncash salaries and consulting expense	13.62K
Warrant issuance costs	0
Change in value of warrant liability
Changes in operating assets and liabilities:
Accounts receivable
Other current assets
Other long term assets
Deposits
Accounts payable
Deferred revenue	-12.68K
Accrued expenses
Accrued bonuses
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of short-term invesments
Purchase of equipment	-7.64K
Costs of patents pending
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock	0
Noncontrolling interest capital contribution to Incuron, LLC
Financing costs on common stock offering
Cash warrant issuance costs
Warrant exercise fees
Exercise of options
Exercise of warrants
Net cash provided by financing activities
Effect of exchange rate change on cash and equivalents	-45.6K
INCREASE IN CASH AND EQUIVALENTS	-1.87M
CASH AND EQUIVALENTS AT BEGINNING OF PERIOD	5.92M
CASH AND EQUIVALENTS AT END OF PERIOD	4.05M

Entities mentioned with CBLI